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Our understanding of the pathogenesis of Paget’s disease of the vulva and the breast remains limited. Current evidence supports
the fact that angiogenesis plays an important role in the pathogenesis of several diseases. Therefore, we sought to deﬁne its role,
as correlated with microvessel density, in Paget’s disease of the vulva and the breast. Microvessels were analysed using anti-von
Willebrand factor antibody in 105 cases of Paget’s disease of the vulva and the breast comprising 71 cases of Paget’s disease of the
vulva, including 8 cases with invasive disease, and 34 cases of Paget’s disease of the breast. The latter included 12 cases with DCIS,
5 cases with both DCIS and invasive carcinoma, and 6 with carcinoma alone. Eleven cases had no underlying tumour identiﬁed.
Increased microvessel density was demonstrated in Paget’s disease of the breast with DCIS and with carcinoma alone compared to
Paget’s disease of the breast alone, P<0.08 and P<0.013, respectively. There were no signiﬁcant diﬀerences in microvessel density
in the vulval cases. Neovascularisation is an important process in the development of Paget’s disease of the breast. Other biological
and molecular processes are more involved in the pathogenesis of Paget’s disease of the vulva.
1.Introduction
The pathogenesis of Paget’s disease of the vulva (PDV) and
Paget’sdiseaseofthebreast(PDB)continuestobeanenigma.
Despite many theories that have been put forward on their
origins and disease progression, the pathogenesis of these
two diseases still remains unclear. PDV is an intraepithelial
in situ carcinoma which accounts for approximately 1% of
all vulval neoplasms [1]. PDB accounts for 0.5–4% of all
breast cancers. They are both characterised by the presence
of large, pale neoplastic (Paget) cells which are seen within
the epidermis of the vulva and the nipple epithelium, respec-
tively. In 10–30% of PDV cases, an invasive adenocarcinoma
is present. This is in contrast to PDB where the general
consensus is that almost all cases are associated with an
in situ or invasive ductal carcinoma. This is based on the
epidermotropic theory; Paget cells are ductal carcinoma cells
that have migrated up from the underlying carcinoma to
the nipple [2]. This theory, however, does not account for
the cases of PDB that have no underlying carcinoma [3].
Toker cells have been described as precursor cells of both
mammaryandextramammaryPaget’sdisease.Thesecellsare
found in the basal layer of the epidermis and are adjacent
to the lactiferous ducts in the nipple [4]. They also occur
as a normal constituent of genital skin in association with
mammary like glands of the vulva [5]. The idea that Toker
cells are precursors of mammary and extramammary Paget’s
diseaseisdisputedbydiﬀerencesinimmunoproﬁleandmor-
phological appearance compared to Paget cells [6, 7]. The
concept that Paget cells are in fact malignant keratinocytes,
which has been transformed in situ, has been put forward as
the transformation theory [8]. The transformation theory is
favoured for the histogenesis for PDV and for those cases in
PDB without an underlying carcinoma.
Angiogenesis is the formation of new capillary blood
vessels from preexisting vasculature. It proceeds and sustains2 Journal of Oncology
tissue growth and as such is an important component in
tumour growth and metastasis. The exact timing of the point
at which angiogenesis occurs, in the growth and progression
of tumours, is known as the angiogenic switch [9]. The
pathwayscontrollingthisswitchtotheangiogenicphenotype
in tumours are dependent on a net eﬀect of stimulators
and inhibitors of angiogenesis [10–12]. This involves cell
migration, matrix degradation by various growth factors,
and the proliferation of the endothelial cells [13–15]. Stim-
ulators of angiogenesis include vascular endothelial growth
factor (VEGF), platelet-derived endothelial growth factor
(PD-ECGF), and angiopoietin [16–18]. Thrombospondin-1,
VEGF inhibitor, and angiostatin are well-known inhibitors
of angiogenesis [19, 20] .I nap r e v i o u ss t u d y ,w ee x a m i n e d
the expression of PD-ECGF/TP and VEGF in PDV and PDB.
PD-ECGF/TP was expressed in 41% of Paget cells in PDV
and 55% in PDB. There was no signiﬁcant diﬀerence in PD-
ECGF/TPexpressioninPDVandPDBwithorwithoutDCIS
or invasive disease. VEGF was not expressed by Paget cells
[21].
Microvessel density (MVD) is a measure of tumour angi-
ogenesis. Increased MVD has been shown to be associated
with disease progression and metastasis in several cancers,
including vulval, breast, and prostate cancers [22–24]. A
variety of endothelial cell markers have been used to identify
microvessels for the purpose of counting. The most com-
monly used include factor-VIII-related antigen (F8RA)/von
Willebrand factor (vWF), CD31/PECAM-1, and CD34.
F8RA forms part of the vWF complex and plays a critical
role in the process of haemostasis [25]. CD31 (PECAM-1),
a platelet-endothelial cell adhesion molecule, is a trans-
membrane glycoprotein involved in cell adhesion [26], and
CD34 is a surface glycoprotein expressed in endothelial cells
in lymphoid tissue [27]. This current study extends our
previousstudiesonPaget’sdiseaseofthevulvaandthebreast.
The aim was to establish whether angiogenesis, as correlated
with microvessel density, is diﬀerent in PDV and PDB with
or without an underlying tumour. The identiﬁcation of an
association between these diseases and angiogenesis would
increase our understanding of the biological processes in-
volved and would help us to move closer in unravelling the
pathogenesis of PDV and PDB.
2.MaterialsandMethods
2.1. Tissue Specimens. Ethical approval was granted by the
R o y a lF r e eH o s p i t a lN H ST r u s t .S e v e n t y - o n ec a s e so fP D V ,
including 8 cases associated with invasive disease, and 34
cases of PDB, which included 12 cases with DCIS alone,
5 cases with both DCIS and invasive carcinoma, 6 with
an underlying invasive carcinoma, and eleven cases of PDB
without a DCIS or an underlying carcinoma (PDB alone),
were analysed for the expression of microvessels using anti-
von Willebrand factor antibody. These cases were retrieved
from the Histopathology Department at the Royal Free
Hampstead NHS Trust and from collaborators as listed in
theacknowledgements.Thecaseswerediagnosedandtreated
between 1984 and 2000.
2.1.1. Immunohistochemistry. Immunohistochemical stain-
ing was performed using the streptavidin-biotin-peroxidase
technique. Brieﬂy, sections were deparaﬃnised in xylene and
rehydrated in diﬀerent percentages of ethanol up to distilled
water for 10min. 3% hydrogen peroxide was placed on the
sections to block endogenous peroxidase for 10min. They
were then placed in distilled water for 10min at 37◦C.
Antigen retrieval was performed using 12.5mg of pro-
teinase (bacterial protease Type 24, Sigma) in 100mL of
phosphate buﬀered saline (PBS) at 37◦C for 10mins. The tis-
sue sections were then incubated at room temperature with
monoclonal anti-human vWF antibody for 1hr (1:40 dilu-
t i o n ;c l o n eF 8 / 8 6 ,D a k o ,E l y ,C a m b s ,U K ) ,f o l l o w e db yi n c u -
bationwiththesecondaryantibody(biotinylatedrabbitanti-
mouse immunoglobulin E0354, Dako), dilution 1:400 for
45min. All sections were then incubated with streptavidin-
biotin-horseradish peroxidase complex (Dako), diluted
1:200 in Tris-buﬀered saline for 30min. Antibody binding
was visualised with a solution containing the chromogen
3,3 -diaminobenzidine (Sigma-Aldrich, Poole, Dorset, UK)
for 8–12min and then terminated with tap water. The
sections were counterstained with Mayer’s haematoxylin
(Merck, Lutterworth, Leics, UK), dehydrated in methanol,
cleared in xylene, and mounted in DPX. Human placenta
was used as positive control, and for negative control, vWF
was replaced with PBS. In this study, we used vWF as the
endothelial cell marker of choice because of its consistent
staining and the fact that it was less likely to react with other
tissuecomponents,suchasmacrophages,comparedtoCD31
and CD34 endothelial cell markers.
2.2. Microvessel Density Assessment. A single countable mi-
crovessel was considered as a brown staining endothelial cell
or endothelial cell cluster that was separate from adjacent
microvessels, tumour cells, and other connective tissue ele-
ments. Large vessels with lumina greater than approximately
seven red blood cells were excluded from the count [28].
Blood vessels were detected by a method similar to Bosari
et al. [28]. Brieﬂy, areas of highest neovascularisation, that
is, containing the highest number of capillaries and small
venules per area (hot spots) were found by scanning the
whole tissue section at low power (×40 and ×100) using a
light microscope. Five ﬁelds in each section with the highest
number of hot spots were selected. The highest vessel density
( H V D )o fﬁ v eﬁ e l d sa t×200 ﬁeld (0.74mm2 under the
light microscope) and ×400 ﬁeld (0.17mm2 under the light
microscope) was recorded, and the average vessel density
(AVD) was also recorded in these ﬁve ﬁelds at ×200 and
×400. This was repeated using the HVD and AVD of three
ﬁelds. The area of HVD and AVD using ﬁve ﬁelds did
not diﬀer signiﬁcantly from the values obtained using three
ﬁelds and therefore the analysis was performed using three
ﬁelds. Individual MVD was made at both ×200 and ×400
magniﬁcation within each hot spot. The MVD is conﬁned
to an area within 500µm of dermal tissue just beneath
the basement membrane of the epidermis and expressed as
HVD/AVD per mm2.
Sections were stained on 3 separate occasions to ensure
reproducibility. Results were analysed by three independentJournal of Oncology 3
Figure 1: vWF expression demonstrating microvessels in PDB with
DCIS (×200). Arrow:Paget cells.
observers (PEE, LFWTF, and JCC). In all cases, there was
<5% variation in results between sections and observers.
2.3. Statistical Analysis. Statistical analysis was performed
usingtheMann-WhitneyU testtocompareMVDexpression
between invasive and noninvasive cases of PDV and cases
of PDB with DCIS and invasive carcinoma. The SPSS v15
software was used to conduct the analysis. A P value of <0.05
was considered signiﬁcant.
3. Results
The vascular endothelial cells were stained brown by the
anti vWF antibody. Figures 1, 2,a n d3 show the Paget cells
and the surrounding stained microvessels in PDB and PDV.
There were signiﬁcant diﬀerences between PDB alone and
PDB with DCIS, P<0.008 at HVD ×400 and P<0.02 at
AVD ×400; and between PDB alone and PDB with invasive
cancer, P<0.013 at HVD ×400 and P<0.009 at AVD ×400.
ThemeanMVD ×400wasalsohigherinPDBwithDCISand
invasivecarcinomacomparedtoPDBalonebutdidnotreach
statistical signiﬁcance. Similarly, the HVD and AVD ×200
magniﬁcation in cases of PDB with DCIS and PDB with
invasive carcinoma were also higher compared to PDB alone.
The mean HVD and AVD values in PDB are summarised in
Table 1.
The mean HVD at 200 and 400 magniﬁcation in PDV
without invasive disease was 28.4 and 7.0, respectively, and
20.3 and 8.6 in PDV with invasive disease. Table 2 demon-
strates the mean values of the MVD in PDV. There appeared
to be no signiﬁcant diﬀerence in the MVD in intraepidermal
PDV as compared with PDV associated with invasive disease.
4. Discussion
MVD has been used in several studies to investigate the role
of angiogenesis in patients with cancer and has been shown
to be a prognostic indicator for several tumours. The role
of angiogenesis, as determined by MVD, has been examined
in vulval lichen sclerosus, vulval intraepithelial neoplasia
Figure 2: vWF expression demonstrating microvessels in PDV
without invasive disease (×200).
Figure 3: vWF expression demonstrating microvessels in PDV
without invasive disease (×200).
(VIN), and vulval cancer [29–31]. MVD was thought to
be valuable prognostic marker for VIN 3 in determining
progression to invasive disease [30]. Increased MVD was
also associated with a poor prognosis in squamous cell car-
cinoma (SCC) of the vulva. It was not a useful parameter
in determining potential malignant progression in vulval
lichen sclerosus. In comparison, another study [32] did not
demonstrate a positive correlation in vulval SCC with stage,
survival, or pattern of invasion.
In breast cancer, there have also been conﬂicting results
reported in the association with MVD and its role as a
prognostic factor. It has been shown that intratumour MVD
is an independent prognostic factor for breast carcinoma.
T h ea u t h o r sf o u n dac o r r e l a t i o nb e t w e e nM V Da n do v e r a l l
and relapse-free survival in patients with early-stage breast
carcinoma [33]. Others have demonstrated the vessel density
to be a signiﬁcant prognostic indicator in node-negative
and node-positive breast cancer [34]. A more recent study
reported an increase in MVD between normal and benign
hyperplastic breast tissue and between in situ and invasive
carcinomas [35]. However, other studies have demonstrated
a lower MVD in the breast carcinoma compared to the4 Journal of Oncology
Table 1: Mean values of the MVD in PDB.
Cases n HVD (×200) AVD (×200) HVD (×400) AVD (×400)
PDB with DCIS 12 26.9 (13.7) 18.3 (12.3) 11.2 (3.1) 8.3 (3.1)
PDB with DCIS/invasive carcinoma 5 14.6 (10.0) 11.7 (8.9) 9.0 (4.6) 7.4 (3.8)
PDB with invasive carcinoma 6 20.8 (6.4) 15.3 (4.8) 17.2 (13.2) 14.3 (11.3)
PDB alone 11 19.1 (13.6) 13.9 (10.2) 7.2 (2.7) 5.1 (2.4)
n:n u m b e ro fc a s e s .T h eS D so ft h em e a na r eg i v e ni nb r a c k e t s .
Table 2: Mean values of the MVD in PDV with and without invasive disease.
Cases n HVD (×200) AVD (×200) HVD (×400) AVD (×400)
PDV without invasive disease 63 28.5 (16.4) 20.0 (14.04) 10.4 (5.9) 7.0 (3.8)
PDV with invasive disease 8 20.4 (19.5) 14.1 (13.3) 12.1 (9.4) 8.7 (5.4)
n:n u m b e ro fc a s e s .T h eS D so ft h em e a na r eg i v e ni nb r a c k e t s .
adjacent normal breast tissue [36] and were unable to ﬁnd
a relationship between MVD and breast metastases [37].
The inconsistent results reported in these studies may be
due to the diﬀerent techniques and endothelial cell markers
used to measure tumour angiogenesis. A double-labelling
technique was used to quantify MVD using CD34 or vWF
[36]. vWF was used as the only endothelial cell marker [36]
and a further study utilised CD31 as the endothelial cell
marker and the Chalkley method to assess MVD [37]. The
Chalkley method measures the relative area of vessel proﬁle
inahigh-density regionofthetumourascomparedtoMVD,
whichmeasuresthedensityofthevessels[38].Hollingsworth
et al. [39] described a method using vascular volume to
assess MVD. Determination of vessel density by vascular
volumerepresentsanaverageoftheentiresectionratherthan
focusing on areas of most intense neovascularisation and
therefore does not reﬂect the angiogenic activity of tumour
cells or metastatic potential. To our knowledge, no other
study has investigated MVD in PDV and PDB. Our ﬁndings
suggest that neovascularisation is an important factor in
the development of PDB but not in PDV. MVD as assessed
by HVD and AVD ×400 magniﬁcation may be a useful
parameter to determine which cases of PDB will have DCIS
orinvasive carcinomadisease present. Identifying thosecases
with a low MVD may allow a more conservative approach in
the surgical management of PDB.
Ad i ﬀerent mechanism may be involved in the growth
and progression of PDV. It is possible that in PDV, Paget
cells can migrate and progress to invasive disease by utilising
the existing vasculature, without the need for the formation
of new blood vessels. This could explain why there was no
diﬀerence in the microvessel counts between PDV with or
without underlying invasive disease. Tumour progression in
the absence of neoangiogenesis has been described by several
authors [40–42]. “Cooption”, the utilisation of preexisting
vasculature by tumours to obtain its blood supply and there-
fore to grow and progress, has been reported in malignant
melanomas, brain metastases, and lung cancer. D¨ ome et al.
[40] demonstrated the incorporation of the existing host
vascular plexus into a progressing malignant melanoma.
Others have described growth of tumour cells in non small
cell carcinoma of the lung without morphological evidence
of neoangiogenesis [43] and the development of brain
metastases, without the induction of sprouting angiogenesis,
even in the presence of high levels of VEGF [41].
It is well documented that the growth and disease
progression of many cancers is due in part to the loss of cell-
cell adhesion. We have demonstrated that the cell adhesion
molecule E-cadherin is signiﬁcantly reduced (P = 0.039) in
Paget’s disease of the vulva cases with invasive disease when
compared with Paget’s disease of the vulva cases without
invasive disease. E-cadherin expression was normal in PDB
and there was no diﬀerence between those cases of PDB with
or without DCIS or invasive disease [44]. These ﬁndings and
the results from this current study demonstrate the critical
steps involved in the pathogenesis of PDB and PDV may
occur by diﬀerent mechanisms.
Inconclusion,thisistheﬁrststudytoassessMVDinPDV
and PDB. MVD can be a useful parameter in determining
the presence of PDB with or without DCIS or invasive
disease. Additional work is needed to assess the relationship
between MVD and other stimulators of angiogenesis in the
pathogenesis of PDB and PDV. What impact the diﬀerences
in the pathogenesis in PDB and PDV, as described in this
study, have on the histogenesis of these two diseases remains
to be clariﬁed.
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